Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours (Q44919924)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours (English)

1 reference

Europe PubMed Central

7 December 2017

0 references

11

object named as

Hakim Bouterfa

1 reference

Europe PubMed Central

7 December 2017

Peter Bartenstein

12

object named as

Peter Bartenstein

1 reference

Europe PubMed Central

7 December 2017

Hans-Georg Buchholz

4

object named as

Hans-Georg Buchholz

1 reference

Europe PubMed Central

7 December 2017

author name string

Andreas Helisch

1

1 reference

Europe PubMed Central

7 December 2017

Gregor J Förster

2

1 reference

Europe PubMed Central

7 December 2017

Helmut Reber

3

1 reference

Europe PubMed Central

7 December 2017

Rudolf Arnold

5

1 reference

Europe PubMed Central

7 December 2017

Burkhard Göke

6

1 reference

Europe PubMed Central

7 December 2017

Matthias M Weber

7

1 reference

Europe PubMed Central

7 December 2017

Bertram Wiedenmann

8

1 reference

Europe PubMed Central

7 December 2017

Stanislas Pauwels

9

1 reference

Europe PubMed Central

7 December 2017

Ulrike Haus

10

1 reference

Europe PubMed Central

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 June 2004

1 reference

Europe PubMed Central

7 December 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

7 December 2017

31

1 reference

Europe PubMed Central

7 December 2017

10

1 reference

Europe PubMed Central

7 December 2017

1386-1392

1 reference

Europe PubMed Central

7 December 2017

https://scigraph.springernature.com/pub.10.1007/s00259-004-1561-6

0 references

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor imaging and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calculation of residence times and radiation doses using the standard PC software Excel

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

1 reference

https://pubmed.ncbi.nlm.nih.gov/15175836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-004-1561-6

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44919924&oldid=2057023778"